Bristol-Myers Squibb Co.'s (BMS) chief scientific officer (CSO), Thomas Lynch, said the firm has not seen any overall survival (OS) data from the phase III Checkmate-227 study, and called the progression-free survival (PFS) data "very fresh to us. We look forward to reporting those at an important medical meeting," and will publish the results in a scientific journal "as soon as we possibly can," he said.